StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ICUI yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $118.83 | $123.08 | +3.58% | 0.4M |
| 05-19 | $123.33 | $123.66 | +0.27% | 0.2M |
| 05-20 | $123.41 | $129.31 | +4.78% | 0.3M |
| 05-21 | $127.37 | $131.31 | +3.09% | 0.3M |
| 05-22 | $131.36 | $133.31 | +1.48% | 0.3M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $530.23M | $1.69B | $1.15B | $604.70M |
Operating Income | $13.58M | $37.19M | $23.48M | $12.89M |
Net Income | $30.13M | $-3.40M | $35.34M | $-15.48M |
EPS (Diluted) | $1.20 | $0.66 | $0.80 | $-0.63 |
Total Assets | $4.01B | $4.10B | $4.11B | $4.18B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $288.33M | $299.73M | $300.02M | $289.70M |
Free Cash Flow OCF − CapEx | $27.61M | $55.85M | $28.22M | $36.71M |
Shares Outstanding | 24.99M | 24.69M | 24.68M | 24.61M |